Cytoreductive nephrectomy in metastatic renal cell carcinoma
- PMID: 38847285
- PMCID: PMC11157663
- DOI: 10.1002/14651858.CD013773.pub2
Cytoreductive nephrectomy in metastatic renal cell carcinoma
Abstract
Background: Nephrectomy is the surgical removal of all or part of a kidney. When the aim of nephrectomy is to reduce tumor burden in people with established metastatic disease, the procedure is called cytoreductive nephrectomy (CN). CN is typically combined with systemic anticancer therapy (SACT). SACT can be initiated before or immediately after the operation or deferred until radiological signs of disease progression. The benefits and harms of CN are controversial.
Objectives: To assess the effects of cytoreductive nephrectomy combined with systemic anticancer therapy versus systemic anticancer therapy alone or watchful waiting in newly diagnosed metastatic renal cell carcinoma.
Search methods: We performed a comprehensive search in the Cochrane Library, MEDLINE, Embase, Scopus, two trial registries, and other gray literature sources up to 1 March 2024. We applied no restrictions on publication language or status.
Selection criteria: We included randomized controlled trials (RCTs) that evaluated SACT and CN versus SACT alone or watchful waiting.
Data collection and analysis: Two review authors independently selected studies and extracted data. Primary outcomes were time to death from any cause and quality of life. Secondary outcomes were time to disease progression, treatment response, treatment-related mortality, discontinuation due to adverse events, and serious adverse events. We performed statistical analyses using a random-effects model. We rated the certainty of evidence using the GRADE approach.
Main results: Our search identified 10 records of four unique RCTs that informed two comparisons. In this abstract, we focus on the results for the two primary outcomes. Cytoreductive nephrectomy plus systemic anticancer therapy versus systemic anticancer therapy alone Three RCTs informed this comparison. Due to the considerable heterogeneity when pooling across these studies, we decided to present the results of the prespecified subgroup analysis by type of systemic agent. Cytoreductive nephrectomy plus interferon immunotherapy versus interferon immunotherapy alone CN plus interferon immunotherapy compared with interferon immunotherapy alone probably increases time to death from any cause (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.51 to 0.89; I²= 0%; 2 studies, 326 participants; moderate-certainty evidence). Assuming 820 all-cause deaths at two years' follow-up per 1000 people who receive interferon immunotherapy alone, the effect estimate corresponds to 132 fewer all-cause deaths (237 fewer to 37 fewer) per 1000 people who receive CN plus interferon immunotherapy. We found no evidence to assess quality of life. Cytoreductive nephrectomy plus tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone We are very uncertain about the effect of CN plus tyrosine kinase inhibitor (TKI) therapy compared with TKI therapy alone on time to death from any cause (HR 1.11, 95% CI 0.90 to 1.37; 1 study, 450 participants; very low-certainty evidence). Assuming 574 all-cause deaths at two years' follow-up per 1000 people who receive TKI therapy alone, the effect estimate corresponds to 38 more all-cause deaths (38 fewer to 115 more) per 1000 people who receive CN plus TKI therapy. We found no evidence to assess quality of life. Immediate cytoreductive nephrectomy versus deferred cytoreductive nephrectomy One study evaluated CN followed by TKI therapy (immediate CN) versus three cycles of TKI therapy followed by CN (deferred CN). Immediate CN compared with deferred CN may decrease time to death from any cause (HR 1.63, 95% CI 1.05 to 2.53; 1 study, 99 participants; low-certainty evidence). Assuming 620 all-cause deaths at two years' follow-up per 1000 people who receive deferred CN, the effect estimate corresponds to 173 more all-cause deaths (18 more to 294 more) per 1000 people who receive immediate CN. We found no evidence to assess quality of life.
Authors' conclusions: CN plus SACT in the form of interferon immunotherapy versus SACT in the form of interferon immunotherapy alone probably increases time to death from any cause. However, we are very uncertain about the effect of CN plus SACT in the form of TKI therapy versus SACT in the form of TKI therapy alone on time to death from any cause. Immediate CN versus deferred CN may decrease time to death from any cause. We found no quality of life data for any of these three comparisons. We also found no evidence to inform any other comparisons, in particular those involving newer immunotherapy agents (programmed death receptor 1 [PD-1]/programmed death ligand 1 [PD-L1] immune checkpoint inhibitors), which have become the backbone of SACT for metastatic renal cell carcinoma. There is an urgent need for RCTs that explore the role of CN in the context of contemporary forms of systemic immunotherapy.
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Conflict of interest statement
PD is the Co‐ordinating Editor of Cochrane Urology; however, he was not involved in the editorial process of this review. OE is a Fellow of Cochrane Urology; however, he was not involved in the editorial process of this review. AU: none LB: none MR is a Contact Editor for Cochrane Urology; however, he was not involved in the editorial process of this review. JL: none FK is a Contact Editor for Cochrane Urology; however, he was not involved in the editorial process of this review.
Update of
- doi: 10.1002/14651858.CD013773
Similar articles
-
Immunotherapy for advanced or metastatic urothelial carcinoma.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013774. doi: 10.1002/14651858.CD013774.pub2. Cochrane Database Syst Rev. 2023. PMID: 37811690 Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Targeted therapy for metastatic renal cell carcinoma.Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. Cochrane Database Syst Rev. 2020. PMID: 33058158 Free PMC article.
-
Radical prostatectomy versus deferred treatment for localised prostate cancer.Cochrane Database Syst Rev. 2020 Jun 4;6(6):CD006590. doi: 10.1002/14651858.CD006590.pub3. Cochrane Database Syst Rev. 2020. PMID: 32495338 Free PMC article.
-
Immunotherapy for metastatic renal cell carcinoma.Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2. Cochrane Database Syst Rev. 2017. PMID: 28504837 Free PMC article. Review.
References
References to studies included in this review
CARMENA {published data only}
-
- Mejean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? European Urology 2021;80(4):417-24. [DOI: 10.1016/j.eururo.2021.06.009] - DOI - PubMed
-
- Méjan A, Escudier B, Thezenas S, Beauval JB, Geoffroy L, Bensalah K, et al. CARMENA: cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-results of a phase III noninferiority trial. Journal of Clinical Oncology 2018;36(18_suppl):LBA3.
EORTC 30947 {published data only}
-
- Mickisch GH, Garin A, Poppel H, Prijck L, Sylvester R, European Organisation for Research Treatment of Cancer Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966-70. [DOI: 10.1016/s0140-6736(01)06103-7] - DOI - PubMed
SURTIME {published data only}
-
- Abu-Ghanem Y, Thienen JV, Blank C, Aarts MJ, Jewett M, Jong IJ, et al. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial. BJU International 2022;130(1):68-75. [DOI: 10.1111/bju.15625] - DOI - PubMed
-
- Bex A, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncology 2019;5(2):164-70. [DOI: 10.1001/jamaoncol.2018.5543] - DOI - PMC - PubMed
-
- Bex A, Mulders P, Jewett M, Wagstaff J, Van Velthoven R, Laguna P, et al. Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME. European Urology Supplements 2018;17(2):e1-2. [DOI: 10.1016/S1569-9056(18)30856-X] - DOI
-
- Bex A, Mulders P, Jewett M, Wagstaff J, Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncology 2019;5(2):164-70. [DOI: 10.1001/jamaoncol.2018.5543] - DOI - PMC - PubMed
-
- Bex A, Mulders P, Jewett MA, Wagstaff J, Van Velthoven R, Laguna Pes PM, et al. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Annals on Oncology 2017;28:v622. [DOI: 10.1093/annonc/mdx440.030] - DOI
SWOG 8949 {published data only}
-
- Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine 2001;345(23):1655-9. - PubMed
References to studies excluded from this review
Abern 2014 {published data only}
-
- Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Research 2014;34(5):2405-11. [PMID: ] - PubMed
Adashek 2021 {published data only}
-
- Adashek JJ, Zhang Y, Skelton WP Iv, Bilotta A, Chahoud J, Zemp L, et al. Dissecting outcomes: should cytoreductive nephrectomy be performed for patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation? Frontiers in Oncology 2021;10:627025. [DOI: 10.3389/fonc.2020.627025] - DOI - PMC - PubMed
Agarwal 2016 {published data only}
Albiges 2019 {published data only}
-
- Albiges L, Rini BI, Haanen J, Motzer RJ, Kollmannsberger CK, Negrier S, et al. Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab 1 axitinib (A 1 Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC). Annals of Oncology 2019;30:v359‐60. [DOI: 10.1093/annonc/mdz249.007] - DOI
Al‐Juhaishi 2022 {published data only}
Andrews 2022 {published data only}
-
- Andrews JR, Lohse CM, Boorjian SA, Leibovich BC, Thompson H, Costello BA, et al. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. Urologic Oncology 2022;40(4):166.e1-e8. [DOI: 10.1016/j.urolonc.2022.01.005] - DOI - PubMed
Arora 2019 {published data only}
-
- Arora S, Sood A, Dalela D, Patel A, Keeley J, Fotouhi A, et al. Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. European Urology 2019;18(1):e1178‐9.
-
- Arora S, Sood A, Dalela D, Patel A, Keeley J, Fotouhi A, et al. Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. Journal of Urology 2019;201(4):e70. [DOI: 10.1097/01.JU.0000555043.11071.bb] - DOI
Bakouny 2020 {published data only}
-
- Bakouny Z, Xie W, Dudani S, Wells C, Gan C L, Donskov F, et al. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): a propensity score-based analysis. Journal of Clinical Oncology 2020;38 Suppl 6:608. [DOI: 10.1200/JCO.2020.38.6_suppl.608] - DOI
Bakouny 2023 {published data only}
-
- Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. European Urology 2023;83(2):145-51. [DOI: 10.1016/j.eururo.2022.10.004] - DOI - PubMed
Bamias 2014 {published data only}
-
- Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, et al. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clinical Genitourinary Cancer 2014;12(5):373-83. [DOI: 10.1016/j.clgc.2014.03.012] - DOI - PubMed
Bell 2022 {published data only}
Bex 2002 {published data only}
Bex 2006 {published data only}
Bex 2011 {published data only}
Bhindi 2018 {published data only}
-
- Bhindi B, Habermann EB, Mason RJ, Costello BA, Pagliaro LC, Thompson RH, et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma. Journal of Urology 2018;200(3):528-34. [DOI: 10.1016/j.juro.2018.03.077] - DOI - PubMed
Bhindi 2020 {published data only}
Blute 2009 {published data only}
-
- Blute ML. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma: Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG, Department of Urology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX. Urologic Oncology: Seminars and Original Investigations 2009;27(1):108-9. [DOI: 10.1016/j.urolonc.2008.11.016] - DOI - PubMed
Borisov 2019 {published data only}
-
- Borisov PS, Orlova RV, Shkolnik MI, Karlov PA, Topuzov EE. Efficacy of incomplete metastasectomy in combination with targeted therapy in metastatic kidney cancer patients. Onkourologiya 2019;15(4):65-72. [DOI: 10.17650/1726-9776-2019-15-4-65-72] - DOI
Capitanio 2013 {published data only}
-
- Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, Briganti A, et al. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy. International Journal of Urology 2013;20(6):572-9. [DOI: 10.1111/iju.12004] - DOI - PubMed
Carvalho 2019 {published data only}
Chatterjee 2017 {published data only}
-
- Chatterjee S, Bansal P, Singh A, Yogendra B, Agarwal S, Rawal SK. Impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy-a performance status based prospective study. Indian Journal of Urology 2017;33 Suppl 1:S43-178. [PMID: ]
Chen 2020 {published data only}
Choi 2023 {published data only}
Conti 2014 {published data only}
CYTOSHRINK 2020 {published data only}
-
- Lalani AA, Swaminath A, Pond GR, Kapoor A, Chu W, Bramson JL, et al. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology 2020;38(Suppl 4):no pagination. [DOI: 10.1200/JCO.2020.38.6_suppl.TPS761] - DOI
de Bruijn 2020 {published data only}
-
- Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, et al. Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data. European Urology Oncology 2020;3(2):168-73. [DOI: 10.1016/j.euo.2019.12.004] - DOI - PubMed
EUCTR2007‐005977‐67‐IT {published data only}
-
- EUCTR2007-005977-67-IT. Sunitinib either before or after cytoreductive nephrectomy. A phase II trial in patients with metastatic renal cell carcinoma. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2007-... (first received 2 November 2008).
Fallah 2024 {published data only}
-
- Fallah J, Gittleman H, Weinstock C, Chang E, Agrawal S, Tang S, et al. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US FDA pooled analysis [Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis. J Natl Cancer Inst. 2024 Mar 14:djae066.]. JNCI: Journal of the National Cancer Institute 2024 Mar 14 [Epub ahead of print]. [DOI: 10.1093/jnci/djae066] - DOI - PubMed
Figlin 2014 {published data only}
-
- Figlin R, Nicolette C, Tannir N, Tykodi SS, Chen D, Master V, et al. Interim analysis of the phase 3 ADAPT trial evaluating Rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology 2017;28 Suppl 5:v404. [DOI: 10.1093/annonc/mdx376.003] - DOI
-
- Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DY, Master V, et al. Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clinical Cancer Research 2020;26(10):2327-36. [DOI: 10.1158/1078-0432.CCR-19-2427] - DOI - PubMed
-
- Figlin RA, Wood CG, ADAPT Study Group. ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC). Journal of Clinical Oncology 2014;32 Suppl 4:449. [DOI: 10.1200/jco.2014.32.4_suppl.449] - DOI
Franklin 1996 {published data only}
-
- Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Seminars in Urologic Oncology 1996;14 Suppl 4:230-6. [PMID: ] - PubMed
Gao 2018 {published data only}
-
- Gao J, Karam JA, Tannir NM, Campbell MT, Tidwell RS, Ahrar K, et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). Journal of Clinical Oncology 2019;37 Suppl 15(15 suppl):4501. [DOI: 10.1200/JCO.2019.37.15_suppl.450] - DOI
-
- Gao J, Karam JA, Tannir NM, Slack R, Ahrar K, Rao P, et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). Journal of Clinical Oncology 2018;36 Suppl 15:4520. [DOI: 10.1200/JCO.2018.36.15_suppl.4520] - DOI
Ghatalia 2021 {published data only}
-
- Ghatalia P, Handorf EA, Deng M, Zibelman MR, Abbosh P, Anari F, et al. Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 2021;39 Suppl 15:4582. [DOI: 10.1200/JCO.2021.39.15_suppl.4582] - DOI
Ghatalia 2022 {published data only}
Grimm 2021 {published data only}
-
- Grimm MO, Oya M, Choueiri TK, Schmidinger M, Quinn DI, Mescam GG, et al. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab+ axitinib (A+ Ax) or sunitinib (S): Results from JAVELIN Renal 101. Annals of Oncology 2021;32:S690-1.
Guo 2021 {published data only}
Hanzly 2014 {published data only}
Hara 2023 {published data only}
Harshman 2013 {published data only}
Jäger 2010 {published data only}
-
- Jäger D, Ma J, Korbenfeld E, Zemanová M, Leonhartsberger N, Stauch K, et al. Predict global non-interventional study: baseline characteristics of RCC patients treated with sorafenib. Annals of Oncology 2010;21:viii291.
Janisch 2020 {published data only}
-
- Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, et al. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Urologic Oncology 2020;38(9):739.e9-15. [DOI: 10.1016/j.urolonc.2020.04.033] - DOI - PubMed
Jonasch 2009 {published data only}
Jung 2018 {published data only}
Kassouf 2009 {published data only}
Kato 2022 {published data only}
-
- Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, et al. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study. International Journal of Clinical Oncology 2022;27(3):563-73. [DOI: 10.1007/s10147-021-02091-8] - DOI - PMC - PubMed
Kim 2019 {published data only}
-
- Kim JK, Kim SH, Song MK, Joo J, Seo S, Kwak C, et al. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: a multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer Medicine 2019;8(7):3401-10. [DOI: 10.1002/cam4.2222] - DOI - PMC - PubMed
Lalani 2020 {published data only}
-
- Lalani A-KA, Swaminath A, Pond GR, Kapoor A, Chu W, Bramson JL, et al. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology 2020;38(6 Suppl):TPS761.
Laru 2021 {published data only}
-
- Laru L, Ronkainen H, Ohtonen P, Vaarala MH. Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010. World Journal of Surgical Oncology 2021;19(1):190. [DOI: 10.1186/s12957-021-02308-0] - DOI - PMC - PubMed
Lenis 2018 {published data only}
Levy 1998 {published data only}
-
- Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. Journal of Urology 1998;159(4):1168-73. [PMID: ] - PubMed
Liu 2020 {published data only}
-
- Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach. World Journal of Urology 2020;38(12):3199-205. [DOI: 10.1007/s00345-020-03107-0] - DOI - PubMed
Ljungberg 2020 {published data only}
-
- Ljungberg B, Sundqvist P, Lindblad P, Kjellman A, Thorstenson A, Hellström M, et al. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology 2020;54(6):487-92. [DOI: 10.1080/21681805.2020.1815833] - DOI - PubMed
Luzzago 2021 {published data only}
-
- Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, et al. Association between systemic therapy and/or cytoreductive nephrectomy and survival in contemporary metastatic non-clear cell renal cell carcinoma patients. European Urology Focus 2021;7(3):598-07. [DOI: 10.1016/j.euf.2020.04.009] - DOI - PubMed
Macleod 2018 {published data only}
-
- Macleod LC, Odisho AY, Tykodi SS, Holt SK, Harper JD, Gore JL. Comparative effectiveness of initial surgery vs initial systemic therapy for metastatic kidney cancer in the targeted therapy era: analysis of a population-based cohort. Urology 2018;113:146-52. [DOI: 10.1016/j.urology.2017.11.014] - DOI - PubMed
Manley 2017 {published data only}
-
- Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. International Brazilian Journal of Urology 2017;43(3):432-9. [DOI: 10.1590/S1677-5538.IBJU.2015.0118] - DOI - PMC - PubMed
Margulis 2008 {published data only}
-
- Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Journal of Urology 2008;180(1):94-8. [DOI: 10.1016/j.juro.2008.03.047] - DOI - PubMed
Mutlu 2014 {published data only}
-
- Mutlu H, Gündüz Ş, Büyükçelik A, Yildiz Ö, Uysal M, Tural D, et al. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clinical Genitourinary Cancer 2014;12(6):447-50. [DOI: 10.1016/j.clgc.2014.06.006] - DOI - PubMed
NCT00715442 {unpublished data only}
-
- NCT00715442. Pre-surgical sutent in renal cell carcinoma (RCC) [Phase II non-randomized pre-surgical study evaluating sunitinib in patients with metastatic renal cell carcinoma (RCC) who are eligible for cytoreductive nephrectomy]. clinicaltrials.gov/study/NCT00715442 (first received 15 July 2008).
O'Malley 2011 {published data only}
-
- O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W 3rd, Pili R, et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 2011;78(3):595-600. [DOI: 10.1016/j.urology.2011.03.009] - DOI - PubMed
Okita 2021 {published data only}
-
- Okita K, Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, et al. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: a multicenter retrospective study. Urologic Oncology 2021;39(12):836.e11-17. [DOI: 10.1016/j.urolonc.2021.08.015] - DOI - PubMed
Patel 2016 {published data only}
-
- Patel N, Woo J, Liss MA, Palazzi KL, Randall JM, Mehrazin R, et al. Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches. Canadian Journal of Urology 2016;23(2):8227‐33. [PMID: ] - PubMed
Patel 2017 {published data only}
Pierorazio 2007 {published data only}
-
- Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU International 2007;100(4):755-9. [DOI: 10.1111/j.1464-410X.2007.07108.x] - DOI - PubMed
Poprach 2020 {published data only}
-
- Poprach A, Holanek M, Chloupkova R, Lakomy R, Stanik M, Fiala O, et al. Cytoreductive nephrectomy and overall survival of patients with metastatic renal cell carcinoma treated with targeted therapy-data from the national renis registry. Cancers 2020;12(10):2911. [DOI: 10.3390/cancers12102911] - DOI - PMC - PubMed
Powles 2011 {published data only}
Powles 2013 {published data only}
Robertson 1990 {published data only}
-
- Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. Journal of Urology 1990;144(3):614-7; discussion 617. [DOI: 10.1016/s0022-5347(17)39537-x] - DOI - PubMed
Shaw 2012 {published data only}
Stroup 2013 {published data only}
-
- Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, et al. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. Urology 2013;81(4):805-11. [DOI: 10.1016/j.urology.2012.10.054] - DOI - PubMed
Walther 1993 {published data only}
Walther 1997 {published data only}
Xu 2019 {published data only}
-
- Xu W-H, Qu Y-Y, Wang H-K, Zhang H-L, Ye D. Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: real-world data from a single Chinese center. Journal of Clinical Oncology 2019;37 Suppl 7:570. [DOI: 10.1200/JCO.2019.37.7_suppl.570] - DOI
Yoshino 2022 {published data only}
-
- Yoshino M, Ishihara H, Nemoto Y, Nakamura K, Nishimura K, Tachibana H, et al. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology 2022;52(10):1208-14. [DOI: 10.1093/jjco/hyac099] - DOI - PubMed
References to studies awaiting assessment
TARIBO {published data only}
-
- Grassi P, Verzoni E, Bearz A, Bracarda S, Bregni M, Buti S, et al. TARIBO trial: cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents. Journal of Clinical Oncology 2017;35(15-suppl):TPS4601. [DOI: 10.1200/JCO.2017.35.15_suppl.TPS46] - DOI
References to ongoing studies
NCT00626509 {published data only}
-
- NCT00626509. Sunitinib before or after surgery in treating patients with metastatic kidney cancer [Sunitinib either before or after cytoreductive nephrectomy in patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00626509 (first received 29 February 2008).
NCT03977571 {published data only}
-
- Lisager L, Ahrenfeldt J, Donskov F, Ljungberg B, Bex A, Lund L, et al. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. BMC Cancer 24 Feb 2024. [DOI: 10.1186/s12885-024-11987-3] - DOI - PMC - PubMed
-
- NCT03977571. Deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: the NORDIC-SUN-Trial [Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: a DaRenCa and NoRenCa trial evaluating the impact of surgery or no surgery. the NORDIC-SUN-Trial]. clinicaltrials.gov/ct2/show/NCT03977571 (first received 6 June 2019).
NCT04510597 {published data only}
-
- NCT04510597. Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial [Phase III trial of immunotherapy-based combination therapy with or without cytoreductive nephrectomy for metastatic renal cell carcinoma (PROBE Trial)]. clinicaltrials.gov/ct2/show/NCT04510597 (first received 12 August 2020).
-
- Parikh M. Clinical trials corner: a new look at cytoreductive nephrectomy. Kidney Cancer 2021;5(2):113-4. [DOI: 10.3233/KCA-210000] - DOI
NCT05753839 {published data only}
-
- NCT05753839. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immuno-oncology era: SEVURO-CN trial (SEVURO-CN). clinicaltrials.gov/show/NCT05753839 (first received March 2023).
Additional references
Bakouny 2023
-
- Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: An observational study from the international metastatic renal cell carcinoma database consortium. European Urology 2023;83(2):145-51. [DOI: 10.1016/j.eururo.2022.10.004] - DOI - PubMed
Bedke 2021
-
- Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. European Urology 2021;79(3):339-42. [DOI: 10.1016/j.eururo.2020.12.005] - DOI - PubMed
Bhindi 2019
-
- Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. European Urology 2019;75(1):111-28. [DOI: 10.1016/j.eururo.2018.09.016] - DOI - PubMed
Chan 2021
Covidence [Computer program]
-
- Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, Available at www.covidence.org.
Dariane 2018
Deeks 2023
-
- Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.
Domagała‐Haduch 2016
Eisenhauer 2009
-
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228-47. - PubMed
EndNote [Computer program]
-
- EndNote. Version X5 or X6 or X7. Thomson Reuters, 1988-2016. Available at www.endnote.com.
Esagian 2021
-
- Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a systematic review and individual patient data meta-analysis. Cancers 2021;13(4):695. [DOI: 10.3390/cancers13040695] - DOI - PMC - PubMed
Garcia‐Perdomo 2018
GRADEpro GDT [Computer program]
-
- GRADEpro GDT. Version accessed prior to 15 May 2024. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
Guyatt 2008
-
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ. GRADE: what is "quality of evidence" and why is it important to clinicians? BMJ (Clinical Research Ed.) 2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE] - DOI - PMC - PubMed
Guyatt 2011
Hall 2021
-
- Hall ME, Bhindi B, Luckenbaugh AN, Laviana AA, Moses KA, Satkunasivam R, et al. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. Cancer Causes Control 2021;32(7):675-80. [DOI: 10.1007/s10552-021-01435-z] - DOI - PubMed
Hanna 2016
-
- Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. Journal of Clinical Oncology 2016;34(27):3267-75. [DOI: 10.1200/JCO.2016.66.7931] - DOI - PMC - PubMed
Heng 2013
-
- Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology 2013;14(2):141-8. [DOI: 10.1016/S1470-2045(12)70559-4] - DOI - PMC - PubMed
Higgins 2002
-
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. - PubMed
Higgins 2003
Higgins 2011
-
- Higgins JP, Altman DG, Sterne JA, editor(s), on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.
Higgins 2019
-
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook/archive/v6. - PMC - PubMed
Iacovelli 2022
-
- Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, et al. Primary tumor shrinkage and the effect on metastatic disease and outcomes in patients with advanced kidney cancer with intermediate or poor prognosis treated with nivolumab plus ipilimumab or cabozantinib. Clinical Genitourinary Cancer 2022;20(5):498.e1-9. - PubMed
Kudoh 1997
-
- Kudoh S, Redovan C, Rayman P, Edinger M, Tubbs RR, Novick A, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. Journal of Immunotherapy 1997;20(6):479-87. - PubMed
Larcher 2019
-
- Larcher A, Wallis CJ, Bex A, Blute ML, Ficarra V, Mejean A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? European Urology Oncology 2019;2(4):365-78. - PubMed
Ljungberg 2024
-
- Ljungberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles RH, et al. EAU Guidelines on Renal Cell Carcinoma. European Association of Urology, 2022. Available from uroweb.org/guidelines/renal-cell-carcinoma (accessed 2 December 2022).
Massari 2018
-
- Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, et al. Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy. Targeted Oncology 2018;13(6):705-14. - PubMed
Mazzaschi 2021
-
- Mazzaschi G, Quaini F, Bersanelli M, Buti S. Cytoreductive nephrectomy in the era of targeted– and immuno– therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. Critical Reviews in Oncology/Hematology 2021;160:103293. [DOI: 10.1016/j.critrevonc.2021.103293] - DOI - PubMed
Moher 2009
Motzer 2002
-
- Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology 2002;20(1):289-96. - PubMed
Motzer 2015
NCI 2020
-
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 (last accessed 24 April 2020).
Parmar 1998
-
- Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. - PubMed
Petrelli 2016
-
- Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clinical Genitourinary Cancer 2016;14(6):465-72. - PubMed
Pilié 2017
Renner 2019
RevMan 2023 [Computer program]
-
- Review Manager Web (RevMan Web). Version 7.10.3. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.
Schünemann 2013
-
- Schünemann HJ, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Research Synthesis Methods 2013;4(1):49-62. - PubMed
Schünemann 2023
-
- Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook.
SEER Cancer Statistics 2024
-
- SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer. seer.cancer.gov/statfacts/html/kidrp.html (accessed 17 May 2024).
Sella 1993
-
- Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato RJ, Markowitz AB, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. Journal of Urology 1993;149(1):19-21. - PubMed
Shinder 2017
Skoetz 2020
-
- Skoetz N, Goldkuhle M, Dalen EC, Akl EA, Trivella M, Mustafa RA, et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. Journal of Clinical Epidemiology 2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015] - DOI - PubMed
Sterne 2016
Takemura 2023
-
- Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2023;S2588-9311(23):00217-1. [DOI: 10.1016/j.euo.2023.10.002] - DOI - PubMed
Tierney 2007
Williamson 2002
-
- Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(22):3337-51. - PubMed
References to other published versions of this review
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials